162 related articles for article (PubMed ID: 37124933)
1. Bioinformatics Analysis of the Prognostic Significance of VPS16 in Hepatocellular Carcinoma and Its Role in Drug Screening.
Gong X; Chen T; Lin C; Ping H; Tong X; Zhang K; Chen Z; Cai C; Lu Z; Ke H
Biomed Res Int; 2023; 2023():2501596. PubMed ID: 37124933
[TBL] [Abstract][Full Text] [Related]
2. Construction of liver hepatocellular carcinoma-specific lncRNA-miRNA-mRNA network based on bioinformatics analysis.
Wang R; Hu X; Liu X; Bai L; Gu J; Li Q
PLoS One; 2021; 16(4):e0249881. PubMed ID: 33861762
[TBL] [Abstract][Full Text] [Related]
3. Integrated Bioinformatics and Experimental Analysis Identified TRIM28 a Potential Prognostic Biomarker and Correlated with Immune Infiltrates in Liver Hepatocellular Carcinoma.
Han J; Wang Y; Zhou H; Ai S; Wan D
Comput Math Methods Med; 2022; 2022():6267851. PubMed ID: 36238495
[TBL] [Abstract][Full Text] [Related]
4. Prognostic, Immunological, and Mutational Analysis of MTA2 in Pan-Cancer and Drug Screening for Hepatocellular Carcinoma.
Huang X; Tan J; Chen M; Zheng W; Zou S; Ye X; Li Y; Wu M
Biomolecules; 2023 May; 13(6):. PubMed ID: 37371463
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of MICALL1 and associates with immune infiltration in liver hepatocellular carcinoma patients.
Yang Y; Zhao W; Du J; Wang Y
Cancer Biomark; 2023; 37(3):147-160. PubMed ID: 37248888
[TBL] [Abstract][Full Text] [Related]
6. Pancancer analysis of oncogenic BARX2 identifying its prognostic value and immunological function in liver hepatocellular carcinoma.
Yu S; Yang Y; Yang H; Peng L; Wu Z; Sun L; Wu Z; Yu X; Yin X
Sci Rep; 2023 May; 13(1):7560. PubMed ID: 37161008
[TBL] [Abstract][Full Text] [Related]
7. Adenosine triphosphate-binding cassette subfamily C members in liver hepatocellular carcinoma: Bioinformatics-driven prognostic value.
Meng X; Dong S; Yangyang L; Wang S; Xu X; Liu T; Zhuang X
Medicine (Baltimore); 2022 Feb; 101(7):e28869. PubMed ID: 35363194
[TBL] [Abstract][Full Text] [Related]
8. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.
He A; Huang Z; Wang J; Lu H; Zhang R; Wu L; Feng Q
Dis Markers; 2022; 2022():3968303. PubMed ID: 35855852
[TBL] [Abstract][Full Text] [Related]
9. CD93 overexpresses in liver hepatocellular carcinoma and represents a potential immunotherapy target.
Jiang Q; Kuai J; Jiang Z; Que W; Wang P; Huang W; Ding W; Zhong L
Front Immunol; 2023; 14():1158360. PubMed ID: 37483608
[TBL] [Abstract][Full Text] [Related]
10. A Pyroptosis-Related Gene Signature to Predict Patients' Prognosis and Immune Landscape in Liver Hepatocellular Carcinoma.
Wang J; Huang Z; Lu H; Zhang R; Feng Q; He A
Comput Math Methods Med; 2022; 2022():1258480. PubMed ID: 35242200
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma.
Tao H; Wang C; Lu C; Ma N; Zhu Y; Xuan S; Zhou X
Genet Res (Camb); 2022; 2022():7236823. PubMed ID: 35919033
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive analysis of the correlation of the pan-cancer gene HAUS5 with prognosis and immune infiltration in liver cancer.
Zhang W; Yang C; Hu Y; Yi K; Xiao W; Xu X; Chen Z
Sci Rep; 2023 Feb; 13(1):2409. PubMed ID: 36765148
[TBL] [Abstract][Full Text] [Related]
13. ANXA10 is a prognostic biomarker and suppressor of hepatocellular carcinoma: a bioinformatics analysis and experimental validation.
Zhang C; Peng L; Gu H; Wang J; Wang Y; Xu Z
Sci Rep; 2023 Jan; 13(1):1583. PubMed ID: 36709331
[TBL] [Abstract][Full Text] [Related]
14. Roles of cuproptosis-related gene DLAT in various cancers: a bioinformatic analysis and preliminary verification on pro-survival autophagy.
Yang Q; Zeng S; Liu W
PeerJ; 2023; 11():e15019. PubMed ID: 36949759
[TBL] [Abstract][Full Text] [Related]
15. Type-1 Na
Zhou YT; Chen H; Ai M; Li SS; Li BY; Zhao Y; Cai WW; Hou B; Ni LL; Xu F; Qiu LY
Life Sci; 2021 Aug; 278():119613. PubMed ID: 34000263
[TBL] [Abstract][Full Text] [Related]
16. The mechanism of LSM2 in the progression of live hepatocellular carcinoma was analyzed based on bioinformatics.
Qin P; Huang H; Wang J; Jiang T; Zeng N; Wang Q; He Y; Zhou Y
Med Oncol; 2023 Aug; 40(9):276. PubMed ID: 37612479
[TBL] [Abstract][Full Text] [Related]
17. Protein Regulator of Cytokinesis 1 (PRC1) Upregulation Promotes Immune Suppression in Liver Hepatocellular Carcinoma.
Zhang C; Xu H; Sui X; Wu T; Chen B; Wang S; Wang X
J Immunol Res; 2022; 2022():7073472. PubMed ID: 35983074
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CISD1 Predicts Worse Survival in Hepatocarcinoma Patients.
Lu T; Li C; Xiang C; Gong Y; Peng W; Chen C
Biomed Res Int; 2022; 2022():7823191. PubMed ID: 35313629
[TBL] [Abstract][Full Text] [Related]
19. Overexpressed Histocompatibility Minor 13 was Associated with Liver Hepatocellular Carcinoma Progression and Prognosis.
Zong RQ; Zhang HY; Li XY; Li YR; Chen Y
Genet Res (Camb); 2022; 2022():7067743. PubMed ID: 36262249
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of diverse programmed cell death patterns in the prognosis, tumor microenvironment and drug sensitivity in hepatocellular carcinoma.
Yu Y; Lou Y; Zhu J; Wang X
Medicine (Baltimore); 2023 Dec; 102(48):e36239. PubMed ID: 38050240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
